Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Development Of Phosphorylated Glucomannan-coated Chitosan Nanoparticles As Nanocarriers For Protein Delivery.

M. Cuña, M. Alonso-Sandel, C. Remuñán-López, J. P. Pivel, J. L. Alonso-Lebrero, M. Alonso
Published 2006 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The aim of the present work was to develop a new nanoparticle carrier, adapted for the oral administration of proteins and their delivery to the immune system. Chitosan and phosphorylated glucomannan were chosen as major constituents of the nanoparticles. Chitosan nanoparticles were formed by ionic gelation and then coated with glucomannan. Two different protocols were adopted for the formation of the glucomannan coating: protocol I, in which chitosan nanoparticles were isolated before their coating; protocol II, in which chitosan nanoparticles were not isolated, but coated with glucomannan in the presence of free chitosan. The results showed that, under the selected formulation conditions, the sizes of the nanoparticles ranged between 170 and 300 nm and their zeta potential values were inverted from positive to negative by the glucomannan coating. The nanoparticles prepared by the two protocols could be freeze-dried, in the presence or absence of cryoprotective agents, preserving their original characteristics. The results of the stability study evidenced the positive role of the glucomannan coating in preventing the aggregation of the nanoparticles in buffered media. Finally, the association of the inmunomodulatory protein complex P1 to the chitosan-glucomannan nanoparticles was investigated. The results showed that the association was not dependent on the chitosan: sodium tripoliphosphate ratio, but it was significantly affected by the presence of sodium phosphate in the protein structure.



This paper is referenced by
10.1016/j.ejpb.2008.02.005
Glucomannan, a promising polysaccharide for biopharmaceutical purposes.
M. Alonso-Sande (2009)
10.1211/jpp.61.12.0004
Chitosan‐tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
A. Hasanovic (2009)
Effects of Glucomannan Isolated From Candida Utilis on Adjuvant Arthritis in Lewis Rats
K. Bauerová (2012)
10.22270/JDDT.V7I5.1479
BILOSOME: A BILE SALT BASED NOVEL CARRIER SYSTEM GAINING INTEREST IN PHARMACEUTICAL RESEARCH
Tanvi Rajput (2017)
10.1039/C7TB00787F
A flexible, ultra-sensitive chemical sensor with 3D biomimetic templating for diabetes-related acetone detection.
L. Wang (2017)
10.2147/IJN.S82558
Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine
Y. S. Elnaggar (2015)
10.1016/j.ijbiomac.2016.09.104
Blends and composites of exopolysaccharides; properties and applications: A review.
A. Hussain (2017)
Gelatin Nanoparticles for Targeted Oligonucleotide Delivery to Kupffer Cells - Analytics, Formulation Development, Practical Application
J. Zillies (2007)
10.1016/j.vaccine.2010.01.011
Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
C. Prego (2010)
10.1016/j.biomaterials.2009.04.001
The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity.
Y. Liu (2009)
10.1007/978-3-7091-1890-0
Environmental Influences on the Immune System
C. Esser (2016)
10.1002/APP.26732
Preparation and characterization of konjac glucomannan/poly(diallydimethylammonium chloride) blend films
J. Lu (2007)
10.1016/B978-0-444-59438-9.00009-6
Chapter 9 – Food safety applications of nanoparticles
S. Ricke (2013)
10.1002/tcr.202000042
Theranostic Approach for the Protein Corona of Polysaccharide Nanoparticles.
Sylvie Skalickova (2020)
10.1081/E-EBPP-120052285
Chitosan-Based Gels: Drug Delivery Systems
J. Zhao (2015)
10.1038/nnano.2007.223
Immunological properties of engineered nanomaterials
M. Dobrovolskaia (2007)
10.1016/j.nano.2013.08.012
Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration.
S. Jain (2014)
10.1007/978-0-387-76554-9_11
Charge Modification of Pharmaceutical Nanocarriers: Biological Implications
N. Nafee (2008)
10.1002/9781119962977.CH11
Chitosan‐Based Systems for Mucosal Delivery of Biopharmaceuticals
S. Al-Qadi (2012)
10.1533/9781845694814.5.644
25 – Chitosan-polysaccharide blended nanoparticles for controlled drug delivery
J. M. Alonso (2008)
10.1002/mabi.200700190
Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules.
M. de la Fuente (2008)
10.1002/9780470571224.PSE439
Oral Delivery of Macromolecules for the Development of Therapeutic Agents
H. Lee (2011)
10.3109/10717544.2010.509357
Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB
Yolanda Parajó (2010)
10.1208/s12249-010-9512-y
Polyethylene Glycol on Stability of Chitosan Microparticulate Carrier for Protein
M. Luangtana-Anan (2010)
10.1016/j.colsurfb.2010.07.053
Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug.
Mi-Kyeong Jang (2010)
10.4274/tjps.galenos.2019.48751
Nanocarriers Used Most in Drug Delivery and Drug Release: Nanohydrogel, Chitosan, Graphene, and Solid Lipid
S. Özkan (2019)
10.1201/B11048-7
Chitosan-Based Gels for the Drug Delivery System
Jin Zhao (2011)
10.1166/JBN.2014.1800
Oral mucosal immunization using glucomannosylated bilosomes.
S. Jain (2014)
10.1007/978-3-319-41421-8_15
Interaction Between Nanoparticles and Plasma Proteins: Effects on Nanoparticle Biodistribution and Toxicity
A. Ilinskaya (2016)
10.2217/nnm.11.41
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro.
A. França (2011)
METHODS OF PROTEIN DELIVERY INTO MAMMALIAN CELLS FOR GENE THERAPY AND GENETIC STUDIES
R. Todorova (2008)
10.1201/B10846-10
Transmucosal and Ocular Drug Delivery
Vasant V. Ranade (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar